What is Ryaltris?
Ryaltris is a prescription nasal spray used for the treatment of nasal allergy symptoms. It contains two active ingredients: olopatadine hydrochloride, an antihistamine, and mometasone furoate, a corticosteroid [1].
When does Ryaltris patent expire?
The primary patents for Ryaltris are set to expire in 2028 in the United States. However, the exact expiry dates for all related patents and exclusivities can vary and may be subject to legal challenges. Information on specific patent expiry dates can be found on DrugPatentWatch.com [2].
Are there generics for Ryaltris currently available?
As of now, there are no generic versions of Ryaltris available in the United States. The drug is still protected by its existing patents and exclusivities [2].
What happens if a Ryaltris generic enters the market?
The introduction of a generic version of Ryaltris would likely lead to a significant decrease in the cost of the medication for patients and healthcare systems. Generic drugs are typically priced much lower than their brand-name counterparts, increasing accessibility and affordability [3].
Can biosimilars enter before patent expiry?
Ryaltris is a small molecule drug, not a biologic. Therefore, the concept of biosimilars, which applies to biologic medications, is not relevant to Ryaltris. Generic versions of small molecule drugs can only enter the market after patent and exclusivity protections expire or are successfully challenged [4].